Please ensure Javascript is enabled for purposes of website accessibility

Why Omeros Corporation Is Up Today

By Todd Campbell – Mar 8, 2016 at 12:43PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The launch of a key late-stage trial for the treatment for a rare disease makes this stock intriguing to investors.


What: After reporting fourth-quarter financial results yesterday and indicating today that it's initiating a late-stage trial for a key drug in its pipeline, Omeros Corporation (OMER 0.93%) is skyrocketing 17.5%.

So what: Omeros Corporation has one drug on the market, Omidria, a therapy for use in cataract and intraocular lens replacement procedures, and in the fourth quarter, sales grew 105% from the third quarter to $6.7 million.

Despite that growth, spending led to a loss of $19.8 million in the quarter, or $0.52 per share. Full-year results were similar. Omidria sales totaled $13.3 million since its launch in April 2015, but expenses more than dwarfed that figure, resulting in a full-year loss of $75 million, or $2 per share.

Management also indicated earlier today that its phase 3 trial of OMS721 for the treatment of atypical hemolytic uremic syndrome (aHUS) has kicked off. That's big news because, while aHUS is rare, it's currently treated with Alexion Pharmaceuticals' (ALXN) Soliris, a drug that hauls in about $2.6 billion annually and growing.

Now what: Management has decided to bring its Omidria sales force in house and those 37 sales people, plus a potentially easing in reimbursement headwinds, has management thinking it can ramp Omidria sales this year.

A bigger opportunity, however, may exist if OMS721's trial pans out. Alexion Pharmaceutical's Soliris is the only FDA-approved therapy for aHUS and it carries a jaw-dropping sticker price of about $537,000 per year in the United States.

Omeros Corporation's OMS721 phase 3 trial will begin enrolling newly diagnosed aHUS patients later this year and the FDA appears willing to expedite the drug's development, agreeing to allow Omeros Corporation to use safety data across various indications, rather than in aHUS alone. Previously, the FDA awarded OMS721 both orphan drug designation and fast-track status, so its pathway to market is clearer than it may have been otherwise. Given the market opportunity, it's little wonder investors are bullish.

Editor's Note: This article has been updated to reflect 105% quarter-on-quarter growth, as opposed to 105% year-over-year growth, for Omidria sales. The Fool regrets the error.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alexion Pharmaceuticals Stock Quote
Alexion Pharmaceuticals
Omeros Stock Quote
$2.18 (0.93%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.